LBL 076
Alternative Names: LBL-076Latest Information Update: 27 Apr 2026
At a glance
- Originator Nanjing Leads Biolabs
- Class Antineoplastics; Fab fragments; Immunoglobulin Fv fragments; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies; Trispecific antibodies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 27 Apr 2026 LBL 076 is available for licensing as of 27 Apr 2026. https://en.leadsbiolabs.com/ (Nanjing Leads Biolabs pipeline, April 2026)
- 06 Dec 2025 Preclinical trials in Multiple myeloma in China (Parenteral) prior to December 2025
- 06 Dec 2025 Pharmacodynamics data from a preclinical trial in Multiple myeloma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)